ProQR Therapeutics N.V (PRQR) concluded trading on Wednesday at a closing price of $4.02, with 52.04 million shares of worth about $209.19 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 111.58% during that period and on October 16, 2024 the price saw a gain of about 122.10%. Currently the company’s common shares owned by public are about 78.46M shares, out of which, 52.75M shares are available for trading.
Stock saw a price change of 114.97% in past 5 days and over the past one month there was a price change of 119.67%. Year-to-date (YTD), PRQR shares are showing a performance of 103.03% which increased to 209.23% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.11 but also hit the highest price of $3.29 during that period. The average intraday trading volume for ProQR Therapeutics N.V shares is 129.38K. The stock is currently trading 108.45% above its 20-day simple moving average (SMA20), while that difference is up 105.16% for SMA50 and it goes to 102.37% higher than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ProQR Therapeutics N.V (NASDAQ: PRQR) currently have 78.46M outstanding shares and institutions hold larger chunk of about 22.15% of that.
The stock has a current market capitalization of $328.35M and its 3Y-monthly beta is at 0.38. It has posted earnings per share of -$0.29 in the same period. It has Quick Ratio of 2.73 while making debt-to-equity ratio of 0.54. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for PRQR, volatility over the week remained 24.68% while standing at 12.16% over the month.
Stock’s fiscal year EPS is expected to rise by 0.18% while it is estimated to decrease by -32.77% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Chardan Capital Markets on November 08, 2023 offering a Buy rating for the stock and assigned a target price of $2 to it. Coverage by JMP Securities stated ProQR Therapeutics N.V (PRQR) stock as a Mkt outperform in their note to investors on March 30, 2023, suggesting a price target of $5 for the stock. On December 22, 2022, Cantor Fitzgerald Upgrade their recommendations, while on February 14, 2022, Citigroup Downgrade their ratings for the stock with a price target of $1.70. Stock get a Hold rating from Stifel on February 11, 2022.
